20/20 Biolabs
Blood testing for cancer screening and inflammation tracking, plus laboratory services for diagnostic developers.
Something off on this page? Send us feedback.
Profile
Offers laboratory-developed blood tests that combine protein biomarkers with proprietary algorithms for cancer screening and inflammation tracking, alongside shared laboratory services and a suspicious-powder screening kit. Most revenue comes from OneTest, whose testing is performed in one Maryland laboratory.
Runs OneTest for Cancer as Standard and Premium laboratory-developed blood tests, combining protein tumor biomarkers with proprietary algorithms to report a likelihood score and guide follow-up imaging, molecular, or tissue testing. Analysis occurs in a CAP-accredited, CLIA-licensed high-complexity laboratory in Gaithersburg, Maryland, using venous or upper-arm capillary samples.
Extends the platform through OneTest for Longevity, which measures inflammation and connects it to diet and lifestyle guidance, and CLIAx, a shared laboratory service for overseas diagnostic developers entering the United States. BioCheck remains a first-responder kit that screens suspicious powders for protein.
Generates most revenue from OneTest through individual, commercial, and professional-health customers. Operations rely on a single Maryland laboratory, external collection partners, licensed BioInfra technology, and the regulatory pathway for laboratory-developed tests.
Company facts
Categories
Key statistics
Year to date −97.4% · Average volume (30d) 110.5K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026Q2 FY26 | −$0.12 | −$0.26 | −116.7% | $636.0K | $730.6K | +14.9% | +0.24% |
| Aug 14, 2026Q2 FY26 | −$0.12 | −$0.26 | −116.7% | $636.0K | $730.6K | +14.9% | +5.86% |
| May 20, 2026Q1 FY26 | −$0.10 | −$0.28 | −180.0% | $779.0K | $353.4K | −54.6% | −6.20% |
| Mar 31, 2026Q4 FY25 | — | −$0.25 | — | — | $538.0K | — | 0.00% |
Financial highlights
| 8 quarters | Q3 FY24 | Q4 FY24 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $361.0K | $536.1K | $418.0K | $538.3K | $353.4K | $730.6K | |
| Gross profit | $24.1K | $163.0K | $145.1K | $130.4K | $62.9K | $304.7K | |
| Operating income | −$1.9M | −$1.2M | −$800.2K | −$912.8K | −$1.4M | −$1.2M | |
| Net income | −$1.9M | −$1.2M | −$825.5K | −$1.3M | −$2.2M | −$1.5M | |
| Diluted EPS | −$0.39 | −$0.26 | −$0.17 | −$0.13 | −$0.20 | −$0.26 | |
| Gross margin | 6.7% | 30.4% | 34.7% | 24.2% | 17.8% | 41.7% | |
| Operating margin | -523.7% | -232.1% | -191.4% | -169.6% | -408.4% | -170.3% |
Balance sheet, Jun 30, 2026Cash & short-term investments $4.5M · Total debt $572.4K · Total assets $6.1M · Shareholders' equity $3.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 12.25M · Float 8.13M · 66.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Jonathan M Cohen | 1.83M | 16.80% | 13D | Mar 10, 2026 |
| Full Succeed International Limited | 651.5K | 6.30% | 13G | Mar 10, 2026 |
| Streeterville Capital LLC | 543.7K | 9.90% | 13G | Feb 25, 2026 |
| Cresset Asset Management, LLC | 264.4K | 2.16% | 13F | May 15, 2026 |
| John Woodson Rollins · director | 24.1K | 0.20% | Form 4 | Feb 24, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- GRAIL
Commercial multi-cancer blood screening with much greater clinical scale.
- Abbott
National multi-cancer blood screening through Cancerguard.
- Guardant Health
Blood-based cancer screening for the same asymptomatic adults.
- Freenome
AI-enabled blood screening and a competing multiomics platform.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| 20/20 Biolabs | $0.6332 | +0.54% | $7.6M | — | — | 3.7 | — |
| GRAIL | $80.00 | −0.01% | $3.43B | — | — | 20.8 | +25.7% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Freenome | $14.60 | −1.22% | $120.6M | — | — | — | — |
| Median | 36.2 | 19.4 | 18.3 | +25.7% |